Oncimmune Share Discussion Threads

[waterloo01] 05/4/2019 08:21

Seems undervalued and under followed.

[waterloo01] 01/4/2019 17:25

RNS explains the weakness in the share price Do they know something we don't or a change strategy from Aviva?

[waterloo01] 19/3/2019 07:18

Rather nice premium @£1.56

[pugugly] 31/10/2018 07:30

Accounts now out

They MUST get their finger out and VERY VERY significantly grow revenue or significant risk (imo) of becoming a cheap Chinese takeaway - That is if (and it certaly appears from management speak) that they have a disruptive cancer diagnostic technology -


Revenue for the year was £240k (2017: £215k)

· Operating expenses before share based charges and exceptional items were £5.56m (2017: £4.88m)

· Loss before tax of £6.34m (2017: £5.32m)

· Net loss for the year was £6.34m (2017: £5.02m)

· R&D costs for the year were £1.08m of which £281k has been capitalised (2017: £1,025k of which £415k has been capitalised)

· Strong cash balance at the period end of £12.95m (2017: £5.1m)

[shearluc] 27/9/2018 08:38

Agreed. Unfortunately issuing this RNS in late afternoon doesn't do much for visibility!

[waterloo01] 25/9/2018 16:04

Decent trial results especially as it says it will directly help drive further sales.

[shearluc] 04/6/2018 08:34

Very positive looking business update!!

[the stigologist] 23/1/2018 07:49

Reads like a profit warning to me

[babbler] 02/1/2018 11:30

Yes was surprised it opened so low...

[soupdragon55] 02/1/2018 10:32

Strangely below the radar today, especially given the premium subscription price of £1.56 for the new shares.

[gersemi] 02/1/2018 07:08

A welcome surprise

[pugugly] 18/12/2017 11:40

No new news - Looks as though may be causing share price retreat - or could there be some bad news leaking ? Do not hold but watching as an area where good diagnostics needed but not sure if this coy has them - If not - or there are better nmore efficient technologies available could be toast - Knowledge ??

[banshee] 20/10/2017 15:03

I wouldn't be a holder currently but the key value metric here would be adoption of the early CDT test in one or more national screening programs, following on from the large 12,000 patient NHS trial currently running - which somehow fails to get a mention in your report.

It's also a concern that they haven't yet announced the improved version of the lung test originally due in q1 AFAIK. Also of great interest ould be the performance of the second generation tests due 'soon', a flexible concept as far as ONC, and many small bios go.

I think their original US distributor went into chapter 11 last year which is supposed to account for the fall in sales.

[walbrock82] 20/10/2017 12:01

I don’t feel comfortable investing in this company because of their previous commercial failure with lung cancer detection kit.
The money raised since 2012 to support operations total £25m, while sales amount to £5m.
Since listing it raised £17.5m, and they have £6.5m in the bank. The level of cash burn is high.
For the full detail analysis, click

[ric_ola] 18/10/2017 08:17

Wed, 18th Oct 2017 07:00
RNS Number : 8772T
Oncimmune Holdings PLC
18 October 2017

18 October 2017



Oncimmune Holdings plc

("Oncimmune" or the "Company")



Distribution Agreement Signed for EarlyCDT®-Lung Kit for Poland



Agreement for screening and indeterminate pulmonary nodule applications with minimum sales commitment of approximately £900,000



Nottingham, UK - 18 October 2017: Oncimmune Holdings plc (AIM: ONC.L), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology, today announces it has signed an exclusive agreement for distribution of its EarlyCDT®-Lung test in Poland with SmartGene, a Polish In Vitro Diagnostic (IVD) distribution company with almost 20 years of experience in laboratory and molecular diagnostics & life sciences.



The agreement allows for the sale of the CE marked EarlyCDT®-Lung kit as a screening test and for the risk assessment of indeterminate pulmonary nodules. The agreement is for an initial term of three years and includes minimum sales commitments of £900,000 over the term of the contract. First sales are expected to commence in early 2018.



Poland is a key European market for EarlyCDT®-Lung, as the country has the highest incidence of lung cancer on the European continent with over 10 million smokers. There are also over one million CT scans performed each year, creating a significant need for risk assessment of indeterminate pulmonary nodules.



Geoffrey Hamilton-Fairley, CEO of Oncimmune, commented: "This distribution agreement, is our fourth in Europe and brings the total minimum sales commitments to £1.4m. We anticipate the signing of a number of further agreements in Europe, and beyond, in the coming months as we continue to deliver on our strategy of generating revenues from our platform technology through multiple products, regions and partners."

[shearluc] 05/6/2017 07:30

More Good News. Everything on-track. All sounds very optomistic

[shearluc] 31/5/2017 07:26

A very important step in the commercialization process. If CDT Early Lung gets taken up by the NHS, and other countries (esp China) into a screening programme then the potential is massive

[banshee] 12/5/2017 10:36

I like this company, but there is some fairly formidable up and coming competition, no-one else can use the antibody approach commercially for a couple more years as ONC have a blanket patent on it, but other methods yeild very good results. That is why the figures for the improved test (and also the next generation tests where they use a baseline reading from the patient before they are ill to improve accuracy) are very important.

Remember sales of CDT Early lung to date over several years have yielded only modest revenues, though that will change if they get incorportated into a national program.

[shearluc] 12/5/2017 09:17

The above presntation is well worth looking at, a concise summary of the current situation with expected Newsflow.

The pipeline of potential products is staggering!

[banshee] 11/5/2017 13:27

The shares here are very illiquid. There should be news of their improved CDT Early Lung test (what you might call the mk2 version) any day. These figures were originally expected in q1.

[shearluc] 10/5/2017 07:32

Interesting. I tried to buy 7500 shares yesterday, the most HL would let me have was 1000, and the offer went up immediately afterwards!

Are we expecting any news imminently?